Cargando…
Fisetin in Cancer: Attributes, Developmental Aspects, and Nanotherapeutics
Cancer is one of the major causes of mortality, globally. Cancerous cells invade normal cells and metastasize to distant sites with the help of the lymphatic system. There are several mechanisms involved in the development and progression of cancer. Several treatment strategies including the use of...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9961076/ https://www.ncbi.nlm.nih.gov/pubmed/37259344 http://dx.doi.org/10.3390/ph16020196 |
_version_ | 1784895665963270144 |
---|---|
author | Kumar, Rachna M. Kumar, Hitesh Bhatt, Tanvi Jain, Rupshee Panchal, Kanan Chaurasiya, Akash Jain, Vikas |
author_facet | Kumar, Rachna M. Kumar, Hitesh Bhatt, Tanvi Jain, Rupshee Panchal, Kanan Chaurasiya, Akash Jain, Vikas |
author_sort | Kumar, Rachna M. |
collection | PubMed |
description | Cancer is one of the major causes of mortality, globally. Cancerous cells invade normal cells and metastasize to distant sites with the help of the lymphatic system. There are several mechanisms involved in the development and progression of cancer. Several treatment strategies including the use of phytoconstituents have evolved and been practiced for better therapeutic outcomes against cancer. Fisetin is one such naturally derived flavone that offers numerous pharmacological benefits, i.e., antioxidant, anti-inflammatory, antiangiogenic, and anticancer properties. It inhibits the rapid growth, invasiveness, and metastasis of tumors by hindering the multiplication of cancer cells, and prompts apoptosis by avoiding cell division related to actuation of caspase-9 and caspase-8. However, its poor bioavailability associated with its extreme hydrophobicity hampers its clinical utility. The issues related to fisetin delivery can be addressed by adapting to the developmental aspects of nanomedicines, such as formulating it into lipid or polymer-based systems, including nanocochleates and liposomes. This review aims to provide in-depth information regarding fisetin as a potential candidate for anticancer therapy, its properties and various formulation strategies. |
format | Online Article Text |
id | pubmed-9961076 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-99610762023-02-26 Fisetin in Cancer: Attributes, Developmental Aspects, and Nanotherapeutics Kumar, Rachna M. Kumar, Hitesh Bhatt, Tanvi Jain, Rupshee Panchal, Kanan Chaurasiya, Akash Jain, Vikas Pharmaceuticals (Basel) Review Cancer is one of the major causes of mortality, globally. Cancerous cells invade normal cells and metastasize to distant sites with the help of the lymphatic system. There are several mechanisms involved in the development and progression of cancer. Several treatment strategies including the use of phytoconstituents have evolved and been practiced for better therapeutic outcomes against cancer. Fisetin is one such naturally derived flavone that offers numerous pharmacological benefits, i.e., antioxidant, anti-inflammatory, antiangiogenic, and anticancer properties. It inhibits the rapid growth, invasiveness, and metastasis of tumors by hindering the multiplication of cancer cells, and prompts apoptosis by avoiding cell division related to actuation of caspase-9 and caspase-8. However, its poor bioavailability associated with its extreme hydrophobicity hampers its clinical utility. The issues related to fisetin delivery can be addressed by adapting to the developmental aspects of nanomedicines, such as formulating it into lipid or polymer-based systems, including nanocochleates and liposomes. This review aims to provide in-depth information regarding fisetin as a potential candidate for anticancer therapy, its properties and various formulation strategies. MDPI 2023-01-28 /pmc/articles/PMC9961076/ /pubmed/37259344 http://dx.doi.org/10.3390/ph16020196 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Kumar, Rachna M. Kumar, Hitesh Bhatt, Tanvi Jain, Rupshee Panchal, Kanan Chaurasiya, Akash Jain, Vikas Fisetin in Cancer: Attributes, Developmental Aspects, and Nanotherapeutics |
title | Fisetin in Cancer: Attributes, Developmental Aspects, and Nanotherapeutics |
title_full | Fisetin in Cancer: Attributes, Developmental Aspects, and Nanotherapeutics |
title_fullStr | Fisetin in Cancer: Attributes, Developmental Aspects, and Nanotherapeutics |
title_full_unstemmed | Fisetin in Cancer: Attributes, Developmental Aspects, and Nanotherapeutics |
title_short | Fisetin in Cancer: Attributes, Developmental Aspects, and Nanotherapeutics |
title_sort | fisetin in cancer: attributes, developmental aspects, and nanotherapeutics |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9961076/ https://www.ncbi.nlm.nih.gov/pubmed/37259344 http://dx.doi.org/10.3390/ph16020196 |
work_keys_str_mv | AT kumarrachnam fisetinincancerattributesdevelopmentalaspectsandnanotherapeutics AT kumarhitesh fisetinincancerattributesdevelopmentalaspectsandnanotherapeutics AT bhatttanvi fisetinincancerattributesdevelopmentalaspectsandnanotherapeutics AT jainrupshee fisetinincancerattributesdevelopmentalaspectsandnanotherapeutics AT panchalkanan fisetinincancerattributesdevelopmentalaspectsandnanotherapeutics AT chaurasiyaakash fisetinincancerattributesdevelopmentalaspectsandnanotherapeutics AT jainvikas fisetinincancerattributesdevelopmentalaspectsandnanotherapeutics |